1. Scrip
  2. >>Business
  3. >>Deals

Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

 
• By Joseph Haas

Deal snapshot: Ovid expects to report Phase III data for its Angelman syndrome drug during Q4 2020. It calls Angelini an ideal European partner; deal leaves Ovid to focus its efforts and resources on the US.

businessman and businesswoman are exchanging document or contract
Ovid/Angelini partnership is the first deal for an Angelman syndrome therapy

Who: Ovid Therapeutics and Angelini Pharma

What: Angelini obtains rights in the EU, UK and Russia to Ovid’s Phase III candidate for Angelman syndrome, a rare

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.